YD Bio and EG BioMed Launch AI-Based Cancer Risk Assessment
YD Bio and EG BioMed have launched an AI-based assessment for 10 cancer risk factors. YD Bio is advancing DNA methylation-based cancer detection technology.
YD Bio and EG BioMed have launched an AI-based assessment for 10 cancer risk factors. YD Bio is advancing DNA methylation-based cancer detection technology.